MTFMT

Across TCGA pan-cancer cohorts, MTFMT Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MTFMT data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MTFMT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MTFMT expression acts as an unfavorable survival marker.

LUSC, SARC, and SKCM are the cancer types where MTFMT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.002	0.776	<.001	24	view →
SARC	DFS	Median	All	0.096	0.611	.005	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MTFMT–LUSC (OS)

Open the LUSC breakdown →